Since the mammalian target of rapamycin (mTOR) is modulated in SARS-CoV-2 infected cells [55], rapamycin, an mTOR inhibitor, can be repurposed at low dosages for the treatment of COVID-19 [56]. The gene discussed is MTOR; the disease is COVID-19.